May Measurement Month 2019: an analysis of blood pressure screening results from Colombia.

Hypertension awareness and control is poor in low- and middle-income countries. Thus, implementing strategies to increase hypertension detection is needed. Colombia participated as one of the 92 countries involved in the third campaign of the May Measurement Month in 2019. Blood pressure (BP) was measured in 48 324 volunteers from 13 departments in Colombia. In total, 27.9% individuals were identified with hypertension. Of those with hypertension, 63.7% were aware of their condition, 60.0% were on antihypertensive medication, and 38.4% had controlled BP. These results showed low levels of awareness, treatment, and control of hypertension in this sample of subjects volunteered to participate, suggest the urgent necessity of implementing programmes to improve the diagnosis and management of hypertension in Colombia.

Dyslipidaemias and their treatment in high complexity centres in Colombia. / Las dislipidemias y su tratamiento en centros de alta complejidad en Colombia.

BACKGROUND AND OBJECTIVE: Data is scarce on the distribution of different types of dyslipidaemia in Colombia. The primary objective was to describe the frequency of dyslipidaemias. The secondary objectives were: frequency of cardiovascular comorbidity, statins and other lipid-lowering drugs use, frequency of statins intolerance, percentage of patients achieving c-LDL goals, and distribution of cardiovascular risk (CVR). MATERIALS AND METHODS: Cross-sectional study with retrospective data collection from 461 patients diagnosed with dyslipidaemia and treated in 17 highly specialised centres distributed into six geographic and economic regions of Colombia. RESULTS: Mean (SD) age was 66.4 (±12.3) years and 53.4% (246) were women. Dyslipidaemias were distributed as follows in order of frequency: mixed dyslipidaemia (51.4%), hypercholesterolaemia (41.0%), hypertriglyceridaemia (5.4%), familial hypercholesterolaemia (3.3%), and low c-HDL (0.7%). The most prescribed drugs were atorvastatin (75.7%) followed by rosuvastatin (24.9%). As for lipid control, 55% of all patients, and 28.6% of those with coronary heart disease, did not achieve their personal c-LDL goal despite treatment. The frequency of statin intolerance was 2.6% in this study. CONCLUSIONS: Mixed dyslipidaemia and hypercholesterolaemia are the most frequent dyslipidaemias in Colombia. A notable percentage of patients under treatment with lipid-lowering drugs, including those with coronary heart disease, did not achieve specific c-LDL goals. This poor lipid control may worsen patient's CVR, so that therapeutic strategies need to be changed, either with statin intensification or addition of new drugs in patients with higher CVR.

El lenguaje de la insuficiencia cardiaca con fracción de eyección preservada en los últimos treinta años: un análisis bibliométrico / The language of heart failure with ejection fraction preserved in the last thirty years: a bibliometric analysis

Resumen Introducción: Los estudios bibliométricos permiten realizar un análisis cuantitativo y cualitativo de la producción científica en un campo determinado. En el área de la cardiología, la producción científica ha crecido sustancialmente durante las últimas décadas; sin embargo, existe poca información acerca del manejo integral de la insuficiencia cardiaca con fracción de eyección preservada (ICFEp). Objetivo: Realizar un análisis bibliométrico que proporcione una evaluación detallada del nivel de producción científica de la ICFEp. Método: Estudio bibliométrico descriptivo en el que se realizó una búsqueda en la literatura científica en los últimos 30 años respecto a la ICFEp, para lo cual se utilizó la estrategia de búsqueda "heart failure" AND "preserved ejection fraction" entre 1988 y 2018 en las bases de datos Web of Science, Scopus y Medline a partir de FABUMED y PubReMiner. Resultados: Se encontraron 2830, 4136 y 7943 publicaciones en las bases de datos Medline, Scopus y Web of Science, respectivamente. Los países destacados por su volumen de publicación fueron los Estados Unidos, el Reino Unido y Alemania. En Latinoamérica, los países más productivos fueron Brasil, Argentina y Chile, mientras que Colombia solo tuvo una publicación. Conclusiones: Este análisis bibliométrico es pionero en señalar la evolución de la investigación científica de la ICFEp en los últimos 30 años. Los resultados obtenidos representan un incentivo a la comunidad científica para priorizar la investigación sobre la ICFEp con el fin de mejorar el abordaje integral de los pacientes y, con ello, su calidad de vida.

Abstract Introduction: Bibliometric studies are defined as the quantitative and qualitative analysis of scientific production in each field. The scientific production in the area of cardiology has had a substantial growth during the last decades. Despite this, there is currently little information about heart failure with preserved ejection fraction (HFpEF). Objective: To provide a detailed assessment of the current status and level of scientific production of HFpEF over the past 30 years. Method: Bibliometric study based in scientific literature concerning HFpEF for the period of 1988 - 2018 using the terms "heart failure" AND "preserved ejection fraction" in the databases of the Web of Science, Scopus and Medline using FABUMED and PubReMiner. Results: We found 2830, 4136 and 7943 publications in Medline, Scopus and Web of Science databases, respectively. The countries with higher scientific production in general were: United States, United Kingdom and Germany. In Latin America, the most productive countries were Brazil, Argentina and Chile. Colombia only had one publication. Conclusions: This is the first bibliometric analysis to highlight the production, evolution and current situation of scientific research about the HFpEF in the last 30 years, a call is made to the scientific community worldwide and especially in our country, Colombia, to focus in the scientific production on this subject. The above mentioned, in order to clarify the pathophysiology, reduce morbidity, mortality and improve the quality of life of patients suffering from HFpEF.